ABUS vs BIIB: Which Stock is Better?

Side-by-side comparison of Arbutus Biopharma Corp and Biogen Inc in 2026

Comparison Updated:

ABUS

Arbutus Biopharma Corp

$4.21

BIIB

Biogen Inc

$165.38

Key Metrics Comparison

MetricABUSBIIBWinner
Market Cap$780.84M$24.26BBIIB
P/E RatioN/A15.09BIIB
EPS (TTM)$N/A$10.96BIIB
Revenue Growth-0.6%0.0%BIIB
Gross Margin-98.9%76.6%BIIB

Analyze ABUS

Full quant analysis

Analyze BIIB

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is ABUS or BIIB a better investment?

Comparing ABUS and BIIB: Arbutus Biopharma Corp has a market cap of $780.84M while Biogen Inc has $24.26B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between ABUS and BIIB?

ABUS (Arbutus Biopharma Corp) and BIIB (Biogen Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: ABUS or BIIB?

Based on P/E ratios, compare detailed valuation metrics on our dashboard.

Which is growing faster: ABUS or BIIB?

BIIB has higher revenue growth at 0.0% vs -0.6% for ABUS.

Which company is more profitable: ABUS or BIIB?

Biogen Inc (BIIB) has higher gross margins at 76.6% compared to -98.9% for ABUS.

Which is the larger company: ABUS or BIIB?

Biogen Inc (BIIB) is larger with a market cap of $24.26B compared to $780.84M for ABUS.

Should I buy ABUS or BIIB in 2026?

Both ABUS and BIIB have investment merit. ABUS trades at $4.21 while BIIB trades at $165.38. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between ABUS and BIIB stock?

Key differences: Market Cap ($780.84M vs $24.26B), P/E Ratio (N/A vs 15.1x), Revenue Growth (-0.6% vs 0.0%), Gross Margin (-98.9% vs 76.6%).

Popular Stock Comparisons